MedTrace Logo

Small Circulating RNA as Molecular Markers of Lung Disease in Cystic Fibrosis

NCT02992080 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-01-03

No results posted yet for this study

Summary

The aim of our study is to assess miRNAs expression profiles in the circuling blood of patients with cystic fibrosis and highlight "signatures" that could reflect the pulmonary status of patients

Conditions

Interventions

OTHER

miRNAs isolation from blood samples of patients and control

Blood sample collection in specific PAXGene tubes

Sponsors & Collaborators

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Caroline RAYNAL, PharmD, PhD · Montpellier University Hospital (CHU Montpellier) Montpellier University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-12
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02992080 on ClinicalTrials.gov